SMSarahi G. Molina

Sarahi G. Molina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarahi G. Molina has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor–Positive Breast Cancer

    by Austin A. Whitman, Rasha T. Kakati, Santiago Haase, Christine H.N.C. Thai, Surya K. Tripathi, Attila T. Szenasi, Elizabeth C. Brunk, Denis O. Okumu, Michael P. East, Sarahi G. Molina, et al.

    Resistance to endocrine therapy (ET) is common in estrogen receptor–positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib treatment suppresses MAPK signaling and enhances sensitivity to ET across ET-sensitive and ET-resistant ER+ cell lines and patient-derived organoids (PDO). Vandetanib treatment reprograms transcription toward a less proliferative, more estrogen-responsive luminal A–like state by enriching ERα chromatin binding at canonical estrogen response elements. Multiplexed kinase inhibitor bead–mass spectrometry revealed kinase network reprogramming, including upregulation of PI3K and HER2 activity, as shared adaptive resistance mechanisms to vandetanib treatment. Cotreatment with the HER2 inhibitor lapatinib further enhanced sensitivity to vandetanib. Using an operating room-to-laboratory short-term ex vivo assay coupled to single-cell RNA sequencing, we demonstrate conserved gene expression changes in primary tumor cells, including increased HER2 activity signatures, following vandetanib treatment. Vandetanib sensitivity signatures were generated from cell line and primary human tumor cells which correlate with vandetanib sensitivity in ER+ PDO and patient-derived xenograft models. Future studies should evaluate whether signatures predict responses in patients with ER+ breast tumors and determine the role of cotargeting HER2 signaling with vandetanib therapy.